prikaz prve stranice dokumenta Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
  Preuzmi
PDF 539.95 KB
Znanstveni rad - Prethodno/kratko priopćenje
Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
Physiological research, 70 (2021), Suppl. 2; S249-S252. https://doi.org/10.33549/physiolres.934725
Starčević Čizmarević, Nada; Kapović, Miljenko; Rončević, Dobrica; Ristić, Smiljana

Povezani objekti
COVID-19 | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Starčević Čizmarević, N., Kapović, M., Rončević, D. i Ristić, S. (2021). Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?. Physiological research, 70. (Suppl. 2), S249-S252. doi: 10.33549/physiolres.934725

Starčević Čizmarević, Nada, et al. "Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?." Physiological research, vol. 70, br. Suppl. 2, 2021, str. S249-S252. https://doi.org/10.33549/physiolres.934725

Starčević Čizmarević, Nada, Miljenko Kapović, Dobrica Rončević i Smiljana Ristić. "Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?." Physiological research 70, br. Suppl. 2 (2021): S249-S252. https://doi.org/10.33549/physiolres.934725

Starčević Čizmarević, N., et al. (2021) 'Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?', Physiological research, 70(Suppl. 2), str. S249-S252. doi: 10.33549/physiolres.934725

Starčević Čizmarević N, Kapović M, Rončević D, Ristić S. Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?. Physiological research [Internet]. 2021. [pristupljeno 27.12.2024.];70(Suppl. 2):S249-S252. doi: 10.33549/physiolres.934725

N. Starčević Čizmarević, M. Kapović, D. Rončević i S. Ristić, "Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?", Physiological research, vol. 70, br. Suppl. 2, str. S249-S252, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:933486. [Citirano: 27.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:933486
Podaci o radu
Naslov (engleski)Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
Naslov (engleski)Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?
AutorNada Starčević Čizmarević
AutorMiljenko Kapović
AutorDobrica Rončević
AutorSmiljana Ristić
MBZ: 142283
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Increasing evidence points to host genetics as a factor in COVID-19 prevalence and outcome. CCR5 is a receptor for proinflammatory chemokines that are involved in host responses, especially to viruses. The CCR5 Δ32 minor allele is an interesting variant, given the role of CCR5 in some viral infections, particularly HIV-1. Recent studies of the impact of CCR5-Δ32 on COVID-19 risk and severity have yielded contradictory results. This ecologic study shows that the CCR5-Δ32 allelic frequency in a European population was significantly negatively correlated with the number of COVID-19 cases (p=0.035) and deaths (p=0.006) during the second pandemic wave. These results suggest that CCR5-Δ32 may be protective against SARS-CoV-2 infection, as it is against HIV infection, and could be predictive of COVID-19 risk and severity. Further studies based on samples from populations of different genetic backgrounds are needed to validate these statistically obtained findings.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prethodno/kratko priopćenje
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPhysiological research
Brojčani podacivol. 70, br. Suppl. 2, str. S249-S252
p-ISSN0862-8408
DOIhttps://doi.org/10.33549/physiolres.934725
URN:NBNurn:nbn:hr:184:933486
Datum objave publikacije2021
ProjektŠifra: uniri-biomed-18-137
Naziv (hrvatski): Farmakogenetika multiple skleroze:odgovor na imunomodulacijsku terapiju
Naziv (engleski): Farmacogenetics of multiple sclerosis: response to disease-modifying therapy
Voditelj: Nada Starčević Čizmarević
Pravna nadležnost: Hrvatska
Financijer: NadSve
Linija financiranja: Sveučilište u Rijeci
URL dokumentahttp://bib.irb.hr/1166388
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-01-26 08:15:24